医学
不利影响
单中心
放射科
腺癌
胰腺导管腺癌
放射治疗
内镜超声
胰腺癌
外科
癌症
内科学
作者
Coen Ysbrand Willink,Sjoerd F.M. Jenniskens,Martijn W.J. Stommel,Marcel J. R. Janssen,John J. Hermans,Harm Westdorp,Cees J. H. M. van Laarhoven,Jurgen J. Fütterer,J. Frank W. Nijsen
摘要
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and lacks local treatment options. This study aimed to assess the feasibility and safety of the first-in-human intraoperative ultrasound-guided intratumoral injection of radioactive holmium-166 microsphere in patients with PDAC. METHODS: Patients with proven PDAC eligible for open surgical resection were included. If resection was abandoned during exploration, study intervention was performed. Feasibility was defined by injection success and on-/off-target radiation. Safety was based on adverse event (AE) monitoring for 12 weeks categorized by severity grade and study attribution. RESULTS: Three of the thirteen included patients received study intervention. Injection was successful in all 3 patients. Mean tumor doses of 5.0, 17.0, and 39.0 Gy and maximum tumor doses of 25.0, 41.0 and 256.0 Gy were achieved. Off-target radiation was found once in the lungs and once in the colon with a mean dose <1.0 Gy. There were no AEs with high study attribution, 16, 14, and 19 AEs with low study attribution, including 3, 2, and 4 AEs with grade ≥3. Holmium-166 microspheres appeared hyperdense on CT. CONCLUSION: Intratumoral injection of holmium-166 microspheres in patients with unresectable PDAC seems feasible and safe. Research into minimally invasive image-guided application is advised.
科研通智能强力驱动
Strongly Powered by AbleSci AI